# Turn Biotechnologies

**Source:** https://geo.sig.ai/brands/turn-biotechnologies  
**Vertical:** BioTech  
**Subcategory:** mRNA Epigenetic Reprogramming  
**Tier:** Emerging  
**Website:** turn.bio  
**Last Updated:** 2026-04-14

## Summary

Raised $29M Series A. Acquired ARMMs vesicular delivery tech (Mar 2025). Delivers mRNA cocktails that transiently reprogram aged cells to youthful epigenetic states without altering DNA.

## Company Overview

Turn Biotechnologies is a longevity company using modified mRNA cocktails to transiently reprogram aged cells back toward a youthful epigenetic state — without permanently altering DNA sequences. The company has raised $29 million in Series A financing and acquired ARMMs (Arrestin Domain-Containing Protein 1 Mediated Microvesicle) technology in March 2025 to significantly upgrade the delivery capability of its mRNA reprogramming platform.

The mRNA reprogramming approach is designed to be reversible and transient: unlike CRISPR or viral gene therapies that make permanent changes to DNA, Turn's mRNA molecules naturally degrade after delivering their cellular reprogramming instructions. This potentially safer profile addresses one of the primary clinical concerns with epigenetic reprogramming approaches — the risk that partial reprogramming might induce inappropriate cell state changes that persist.

Turn's dermatology beachhead — applying mRNA reprogramming to aged skin cells to demonstrate in vivo rejuvenation before advancing to systemic conditions — is a clinically accessible first proof point. Skin is directly observable, has established outcome metrics, and allows safety assessment without the systemic monitoring required for internal tissue reprogramming. The ARMMs acquisition significantly upgrades the mRNA delivery system, improving cellular uptake and reducing immune response to the delivery vehicle.

## Frequently Asked Questions

### What does Turn Biotechnologies do?
Delivers modified mRNA cocktails that transiently reprogram aged cells to youthful epigenetic states — reversible reprogramming without permanent DNA alteration, starting with dermatology applications.

### How much has Turn raised?
$29M Series A. Acquired ARMMs vesicular delivery technology in March 2025 to upgrade mRNA delivery capability.

### Why is mRNA reprogramming potentially safer than viral approaches?
mRNA naturally degrades — the reprogramming effect is transient and reversible, unlike viral gene therapy or CRISPR edits that make permanent DNA changes. Lower risk of inappropriate persistent cell state changes.

### Why start with dermatology?
Skin cells are directly observable, have established outcome metrics, and allow safety assessment without systemic monitoring — an accessible first proof point before advancing to internal tissue reprogramming.

### How does Turn Biotechnologies' mRNA epigenetic reprogramming work?
Turn Biotechnologies delivers mRNA encoding epigenetic regulators (Yamanaka factors or specific epigenetic enzymes) via lipid nanoparticles to aged tissues. The mRNA is transiently expressed — reprogramming epigenetic marks back toward a youthful pattern — then degraded, with cells retaining the rejuvenated epigenetic state. Unlike viral delivery of reprogramming factors (used in mouse longevity studies), mRNA delivery enables fine control of expression duration and eliminates integration risk.

### Why did Turn Biotechnologies start with dermatology?
Skin is an ideal first clinical target for epigenetic reprogramming: it's accessible for topical or intradermal delivery (avoiding systemic delivery challenges), aging effects are visible and objectively measurable (epidermal thickness, collagen density, wrinkle metrics), skin cells turn over rapidly so rejuvenation signals appear quickly, and the cosmeceutical/dermatology market supports high pricing without insurance reimbursement hurdles. Success in skin provides proof-of-concept that translates to systemic aging targets.

### How much has Turn Biotechnologies raised?
Turn Biotechnologies has raised Series A and B funding from longevity and biotech investors. The company is part of the well-funded longevity ecosystem alongside Altos Labs (which overlaps scientifically) and Retro Biosciences, and has published peer-reviewed research on mRNA-driven epigenetic reprogramming demonstrating rejuvenation of aged human cells in vitro — providing scientific validation for the approach.

### What are the long-term systemic applications Turn Biotechnologies envisions?
Beyond dermatology, Turn envisions systemic applications: IV-delivered mRNA LNPs that accumulate in the liver (rejuvenating hepatocytes and immune cells), topical application to joints or eyes (local tissue rejuvenation), and potentially inhaled delivery to lung epithelium. The vision is a periodic rejuvenation treatment — perhaps annually or every few years — that resets epigenetic aging across multiple tissues, extending healthspan by maintaining tissue function rather than treating individual age-related diseases.

## Tags

healthtech, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*